| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now.
|
|
Today’s Big NewsApr 25, 2025 |
| By Angus Liu Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in its partner Summit Therapeutics aren’t taking the result too well. |
|
|
|
By Darren Incorvaia Days after the Women’s Health Initiative, one of the largest and longest-running women’s health studies in the world, announced that the Department of Health and Human Services was terminating some of the initiative’s funding, the agency has reversed course. |
By Fraiser Kansteiner AbbVie aims to invest $10 billion in the U.S. through 2035 to support its current growth plans and expand into new areas like obesity, the company’s CEO, Rob Michael, said on a call Friday. |
By Darren Incorvaia Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping further attempts in the indication as a result. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now.
|
|
By Fraiser Kansteiner Amgen is plugging $900 million into an expansion of its biomanufacturing facility in New Albany, Ohio. The project is expected to bring the total number of Amgen jobs in the state to 750 and increase the company’s overall investment in Ohio to more than $1.4 billion. |
By James Waldron Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at least for the time being. |
By Conor Hale In an analysis of Hologic's Genius AI platform, researchers said their findings could help optimize the imaging algorithms used in breast cancer detection and diagnosis. |
By Darren Incorvaia Caribou Biosciences is winnowing down for the second time in less than a year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates. |
By Zoey Becker As potential HIV policy changes, looming tariffs and sweeping cuts across federal drug and health agencies are posing a concern for investors, Gilead is engaging with policymakers to stress the importance of lenacapivir for PrEP, CEO Daniel O'Day said. |
By Darren Incorvaia,Zoey Becker The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will retire from the top role within the next year, once a successor is found. Stoffels joined the company in 2022 after more than 13 years at Johnson & Johnson. |
Fierce podcastsDon’t miss an episode |
| | Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Wednesday, May 28, 2025 | 11am ET / 8am PT Join us to learn more about Integrated Drug Discovery (IDD), and explore the complexity of integrating multidisciplinary functions, including chemistry, biology, pharmacology, project and data management, advanced technologies, and regulatory compliance. Learn how to navigate the drug discovery journey and overcome common challenges. Register now.
|
|
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperIs your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
